Rapidly Translate Innovative Research
We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.
Develop a Pipeline Optimized for Combination
Immunogenesis is focused on developing a pipeline of drugs that, in combination, will synergize to address the critical ingredients for effective immunity against "cold" tumors: 1) Generation of sufficient anti-tumor T cells; 2) protection and expansion of those cells in the tumor; and 3) reduction in hostile tumor metabolism.
Conduct Biomarker-Driven Clinical Trials
We plan our clinical studies to treat patient populations most likely to experience optimal benefit. Further, we leverage novel imaging, and cellular and molecular analysis to understand the mechanisms driving response versus resistance.
Founder, Dr. Michael A. Curran, is a pioneer in modern immuno-oncology. Dr. Curran was the first to describe and drove early clinical development of the PD-1/CTLA-4 inhibitor combination approach, still the most effective clinical combination of immunotherapies.
Technology based on the work of Dr. Curran’s lab at MD Anderson where he has focused on developing approaches to overcome immunotherapy resistance in immunologically “cold” tumors.
Experienced management team and Board of Directors with track record of driving successful results in Biotech.
Founder and SAB Head
Dr. Michael Curran is an Associate Professor of Immunology at the MD Anderson Cancer Center in Houston Texas and co-Scientific Director of the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) program coordinating development and production of clinical immunotherapeutic antibodies. Dr. Curran received the Ph.D. degree from Stanford University training in the laboratory of Dr. Gary Nolan where he was awarded the McDevitt prize for the best graduate thesis in his year. Dr. Curran was the first recipient of the prestigious American Cancer Society Levy Fellowship to fund his post-doctoral studies in the lab of Dr. James P. Allison. While pursuing his postdoctoral studies at Memorial Sloan-Kettering Cancer Center, Dr. Curran published several influential manuscripts describing how T cell co-stimulatory pathways could be modulated, in tandem, to mediate immunologic rejection of melanomas in mice. Dr. Curran described how combination blockade of the T cell co-inhibitory receptors CTLA-4 and PD-1 promoted the rejection of most murine melanomas. This work supported the launch of a Phase I clinical trial in which greater than 50% of metastatic melanoma patients experienced objective clinical responses – a result so unprecedented that this became the first FDA-approved immunotherapy combination. In addition, his subsequent immunologic studies of 4-1BB agonist antibodies earned him the Society for the Immunotherapy of Cancer’s prestigious Presidential Award. The Curran Lab seeks to discover the underlying mechanisms of immune resistance in the “coldest” tumors, pancreatic and prostate adenocarcinoma and glioblastoma, so that rational therapeutic interventions can be developed to restore T cell infiltration and sensitivity to T cell checkpoint blockade.
Before joining Geneos, Jim drove the development of Inovio’s Immuno-Oncology (IO) product strategy. In this effort, he led a cross-functional team across Commercial, Clinical, Product Development, R&D and Business Development to establish a set of key strategic principles. Jim drove the product prioritization efforts based on these principles, established the IO Advisory Panel, and drove KOL and pharma partner interactions to position the company to embark on major clinical programs across four tumor types of interest. These programs are evaluating combination regimens of Inovio’s cancer immunotherapies with PD-(L)1 inhibitors from 3 different pharma partners – Jim drove the establishment of two of these three partnerships as well as a clinical partnership with the Parker Institute for Cancer Immunotherapy.
Prior to Inovio, Jim was at Bristol-Myers Squibb where he was the Payer Marketing Lead for YERVOY®, the pioneering cancer immunotherapy whose approval set off the current wave of immunotherapy development in Oncology. Given the “First in Class” nature of the product and premium price associated with it, Jim created a number of innovative programs to optimize market access. While at BMS, Jim also worked on the overall IO franchise commercial strategy including the development of communication planning for the groundbreaking immunotherapy, OPDIVO®. Prior to BMS, Jim spent 8 years at Merck working in commercial leadership roles with increasing responsibility for the Oncology franchise.
Jim received a MBA (strategy and marketing) with honors from the Tepper School of Business at Carnegie Mellon University. He was awarded the Dean’s Scholarship from Tepper. Jim received his Bachelor of Arts in Math and Economics from Colgate University where he was awarded the Alumni Memorial Scholarship and he graduated Summa Cum Laude.
Dr. William Tanner joined ImmunoGenesis following his tenure at Cantor Fitzgerald as Managing Director and Senior Biotechnology Analyst in the Equity Research Department. Dr. Tanner spent more than 20 years as an analyst at leading healthcare investment banks including SG Cowen, Leerink Swann and Lazard Capital Markets. During his career, Dr. Tanner covered more than 100 biotech companies and was involved in raising billions of dollars for public and private companies. He received the Ph.D. degree from Texas A&M University and completed post-doctoral training at the Washington University School of Medicine in the Department of Cell Biology and Physiology, studying growth factor regulation of mammalian glucose transport, and in the Department of Pathology, Center for Immunology, studying signal transduction mechanisms of growth factor receptors. He was the recipient of a National Research Service Award from the NIH. Prior to starting his Wall Street career, Dr. Tanner received the MBA degree from the Olin School of Business at Washington University.
Investors & Media
ImmunoGenesis Awarded $15.5 M Grant from Cancer Prevention and Research Institute of Texas (CPRIT)
August 24, 2020ImmunoGenesis, Inc. has been awarded a $15.5 M grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance development of IMGS-001, the company’s dual specific Checkpoint Inhibitor and Tumor Microenvironment (TME) remodeling agent.